Dechra Regulatory

Dechra is a leading international specialist veterinary pharmaceuticals and related products business focused on high-value, niche therapeutic areas. The company holds market-leading positions in veterinary endocrinology, dermatology, cardiology, and analgesia for companion animals, while also providing essential products for equine and food-producing animals. Dechra operates a robust global supply chain with specialized manufacturing facilities in the United Kingdom, United States, and Europe. In early 2024, the company was taken private in a multi-billion dollar acquisition by the private equity firm EQT to further accelerate its international growth and product development. Dechra is widely recognized for its gold-standard treatments, such as Vetoryl and Felimazole, which address complex chronic conditions in pets.